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1. INTRODUCTION {#cas14032-sec-0001}
===============

According to a recently published report of cancer incidence and mortality in China, lung cancer is still the most common cancer nationwide, and is the leading cause of cancer death.[1](#cas14032-bib-0001){ref-type="ref"} Over the past decade, targeted therapy has played an important role in oncology, significantly prolonging the survival time of cancer patients, as well as improving their quality of life. Driven gene mutations are important causes of lung cancer and predictors of targeted therapy, such as osimertinib for EGFR‐mutated advanced non--small cell lung cancer (NSCLC) patients[2](#cas14032-bib-0002){ref-type="ref"} and crizotinib for ALK‐positive lung cancer patients.[3](#cas14032-bib-0003){ref-type="ref"}

Non--small cell lung cancer accounts for approximately 85% of all lung cancers,[4](#cas14032-bib-0004){ref-type="ref"} which are relatively insensitive to chemotherapy compared to small cell lung cancer. For NSCLC patients with gene mutations, such as EGFR or ALK mutations, targeted therapy has already become the first line treatment.[5](#cas14032-bib-0005){ref-type="ref"} However, acquired resistance to targeted drugs is inevitable, and chemotherapeutic agents or immune checkpoint inhibitors will be used as alternative drugs after the failure of targeted therapy or combined drugs in the treatment.[6](#cas14032-bib-0006){ref-type="ref"}, [7](#cas14032-bib-0007){ref-type="ref"}, [8](#cas14032-bib-0008){ref-type="ref"} As genotyping becomes increasingly common, it is necessary to understand the sensitivity of patients with different mutation types to different chemotherapeutic agents or immune checkpoints inhibitors.

Due to the short history of conventional genotyping, there are few studies that have reported on the relationship between different genotypes and non--targeted drugs. However, as alternatives to actual drug efficacy indicators, some known drug resistance markers or sensitive markers can predict the efficacy of certain drugs. For example, high levels of ribonucleotide reductase subunit M1 (RRM1) have been associated with resistance to gemcitabine.[9](#cas14032-bib-0009){ref-type="ref"} Programmed death‐ligand 1 (PD‐L1) positive expression enhanced the efficacy of nivolumab in patients with advanced non--squamous NSCLC.[10](#cas14032-bib-0010){ref-type="ref"}

Our study analyzes the relationship between different genotypes and the expression of some known predictive markers, thus providing information critical for individualization of immunotherapy and chemotherapy.

2. MATERIALS AND METHODS {#cas14032-sec-0002}
========================

2.1. Patients and samples {#cas14032-sec-0003}
-------------------------

A total of 785 patients diagnosed with NSCLC with pathologic stage I to IVA disease were included continuously from March 2016 to November 2017 at the First Affiliated Hospital of Guangzhou Medical University. All patients underwent radical resection for lung cancer, and formalin‐fixed paraffin‐embedded (FFPE) specimens were collected from the patients. Two pathologists (Dr He and Dr Gu), who were unaware of the clinical data, independently reviewed the specimens to confirm the histological subtype, staining intensity and tumor cell content. Other relevant information, including age and gender, were also collected. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Guangzhou Medical University. All the patients in this study provided written informed consent.

2.2. Next‐generation sequencing‐based genomic profiling {#cas14032-sec-0004}
-------------------------------------------------------

The specimens were reviewed to ensure tissue adequacy (\>20% tumor nuclei) before testing. DNA was extracted from unstrained FFPE sections using the QIAamp DNA FFPE Tissue Kit (Qiagen, Duesseldorf, Germany) following the manufacturer\'s instructions. DNA concentration was measured using a Qubit Fluorometer (Thermo Fisher, MA, USA). A targeted next‐generation sequencing method was used to identify the clinically relevant mutation profiles. Briefly, FFPE DNA was used for library construction. Hybridization capture of relevant introns and exons from *EGFR* 19del, *EGFR* L858R, *EGFR* rare, *ALK*,*HER2*,*RAS*,*RET*,*ROS1*,*BRAF* and *MET* was performed. The hybrid capture libraries were then sequenced to \>5009 average unique coverage using Ion Proton Sequencers (Thermo Fisher). Sequencing data were processed using a customized bioinformatics pipeline named Otype, which was designed to simultaneously detect single nucleotide variations, short insertions and deletions, copy number variations and gene rearrangements. Finally, data interpretation was focused on genomic alterations associated with clinically available targeted treatment options according to the standards and guidelines of the NCCN, the Association for Molecular Pathology (AMP), the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP).

2.3. Histological analysis {#cas14032-sec-0005}
--------------------------

The pathologic records of the specimens and all available HE‐stained tissue sections, in addition to any available sections with special stains or immunohistochemical (IHC) analysis, were reviewed. Pathological information was collected, including maximum tumor sizes (in cm) and pathologic disease stages. Staging was based on the guidelines of the 7th edition of the TNM classification for lung cancer.[11](#cas14032-bib-0011){ref-type="ref"}

2.4. Immunohistochemical staining {#cas14032-sec-0006}
---------------------------------

Tumor sections were incubated with specific monoclonal antibodies against excision repair cross‐complementation group 1 (ERCC1) epitope (clone UMAB8, Beijing Zhongshan Golden Bridge Biotechnology), RRM1 epitope (clone EP242, Beijing Zhongshan Golden Bridge Biotechnology), thymidylate synthase (TS) epitope (clone TS1, Beijing Zhongshan Golden Bridge Biotechnology) and β‐tubulin‐III epitope (clone TUJ1, Fuzhou Maxim Biotechnology Development).

Immunohistochemical staining showed brown‐yellow granules localizing in the cytoplasm or the nucleus (different antibody with different localization). The grading of IHC positive reaction was based on the criterion of combining the staining intensity and the percentage of positive cells. Five images were randomly acquired at a magnification of ×400 for each specimen. We try to avoid the marginal zone to prevent the edge effect from affecting the evaluation. The number of all cells and positive cells were counted by using the micro‐measurement grid, and the average proportion of positive cells was calculated. First, a score was given according to the staining intensity: 0 if colorless, 1 if light yellow, 2 if light brown, and 3 if dark brown. Then, the percentage of positive cells was calculated for each specimen, and a proportion score was assigned (0 if 0%, 1 if 0% to 10%, 2 if 10% to 50%, 3 if 50% to 75% and 4 if \>75%). Finally, this proportion score was multiplied by the staining intensity score to obtain a final semi quantitative score, which was divided into 4 grades: −(0,1,2), +(3,4), ++(6,8) and +++(9,12). Tumors with a final score exceeding 3 were deemed IHC‐positive. With regard to protein expression, − \~ + is considered low expression and ++\~+++ is considered high expression.

VENTANA PD‐L1 (SP142) Assay (Roche, Basel, Switzerland) was used for the IHC assessment of the PD‐L1 protein in tumor cells in FFPE tumor tissue stained with the OptiView DAB IHC Detection Kit and the OptiView Amplification Kit on a VENTANA BenchMark IHC/ISH instrument. The proportion of tumor area occupied by PD‐L1 expressing tumor cells (%TC, ≥1%) of any intensity was considered PD‐L1 positive.

2.5. The correlation between each driver mutation and the sensitivity markers {#cas14032-sec-0007}
-----------------------------------------------------------------------------

R studio 19.0 (R Studio) and R package ComplexHeatmap were used to generate the heatmap plot and complete linkage clustering was used to perform the hierarchical clustering of the marker expression and present the relationship between genetic features and predictive markers. We calculated the prevalence of 8 important NSCLC‐related driver genes in all the samples, and mutations were grouped according to the mutation with highest abundance in the patient. According to the gene mutations, a low expression rate (ERCC1, RRM1, TS and β‐tubulin III) or a positive rate (PD‐L1) of the predictive markers were also calculated in each subgroup. The overall percentage was used as a reference cut‐off for each sensitivity marker.

2.6. Pilot validation {#cas14032-sec-0008}
---------------------

Another 21 patients with wild‐type (pan‐negative) advanced NSCLC were divided into 2 groups based on the treatment. Group A used anti--microtubule agents, such as docetaxel or paclitaxel, while group B used antimetabolic agents, such as gemcitabine or pemetrexed. The depth of response (DoR) and the objective response rate (ORR) were calculated as tumor remission indicators to show the drug efficacy.

2.7. Statistical analysis {#cas14032-sec-0009}
-------------------------

Statistical analysis was performed using R studio 19.0 and IBM SPSS Statistics 22.0 (SPSS). The *t* test, the χ^2^‐test and Fisher\'s exact test were used according to the variable type. A 2‐tailed *P*‐value of \<0.05 was considered statistically significant.

3. RESULTS {#cas14032-sec-0010}
==========

3.1. Baseline characteristics {#cas14032-sec-0011}
-----------------------------

This study included 438 male and 347 female NSCLC patients, with a median age of 59.1 years old. There were 638 adenocarcinomas, accounting for approximately 80.0% of all the histological types, as well as 67 squamous‐cell carcinomas and 14 lymphoepithelioma‐like carcinomas. Approximately 60.0% of these patients were stage I. The clinicopathological characteristics of patients are summarized in Table [1](#cas14032-tbl-0001){ref-type="table"}. In addition, the examples representing different expression levels of each marker are demonstrated in Figure [1](#cas14032-fig-0001){ref-type="fig"}.

###### 

Baseline characteristics of non--small cell lung cancer patients (N* *=* *785)

                                     Frequency                                Percentage(%)
  ---------------------------------- ---------------------------------------- ---------------
  Sex                                                                         
  Male                               438                                      55.80
  Female                             347                                      44.20
  Age (years)                        mean($\overline{X}$ ± *S*) 59.1 ± 10.7    
  Histology                                                                   
  Squamous carcinoma                 67                                       8.54
  Adenocarcinoma                     638                                      81.27
  Adenosquamous carcinoma            8                                        1.02
  Lymphoepithelioma‐like carcinoma   14                                       1.78
  Large cell lung cancer             4                                        .51
  Mixed small cell lung cancer       6                                        .76
  Others/undefined                   48                                       6.11
  Clinical stage                                                              
  I                                  468                                      59.62
  II                                 164                                      20.89
  III                                136                                      17.32
  IVA                                17                                       2.17
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![The examples representing different expression levels of ERCC1, RRM1, TS, β‐tubulin III and PD‐L1. −\~+, ++ and +++ measure the expression of ERCC1, RRM1, TS and β‐tubulin III. 1%, 50% and 100% for PD‐L1](CAS-110-2014-g001){#cas14032-fig-0001}

3.2. Distribution of different mutations {#cas14032-sec-0012}
----------------------------------------

A total of 498 (63.4%) patients had at least 1 driver gene alteration; 34 patients had compound mutations. Only the mutation with highest abundance is considered for patient classification (Table [S1](#cas14032-sup-0001){ref-type="supplementary-material"}). The prevalence of each benchmark driver mutation is shown in Table [2](#cas14032-tbl-0002){ref-type="table"}. Wild‐type patients have the highest proportion, 36.6%, followed by EGFR L858R, 23.2%, and EGFR 19del, 21.4%.

###### 

The prevalence of driver mutations

  Type         Prevalence (%)
  ------------ ----------------
  Total        785 (100)
  Wild type    286 (36.56)
  EGFR 19DEL   168 (21.40)
  EGFR L858R   182 (23.18)
  EGFR rare    19 (2.42)
  RAS          77 (9.81)
  ALK          25 (3.18)
  RET          9 (1.15)
  ROS1         8 (1.02)
  BRAF         5 (0.64)
  MET (mut)    3 (0.38)
  HER2         2 (0.25)

Concurrent mutations were grouped according to the mutation with highest abundance.

John Wiley & Sons, Ltd

3.3. Correlation between driver mutations and predictive markers {#cas14032-sec-0013}
----------------------------------------------------------------

Correlation between driver mutations and predictive markers is summarized in Figure [2](#cas14032-fig-0002){ref-type="fig"} and Table [3](#cas14032-tbl-0003){ref-type="table"}. For example, wild‐type, EGFR rare mutation, ALK fusion, RAS mut, RET fus and MET mut had higher proportions of lower ERCC1 expression, which indicated that these genotypes might be more sensitive to platinum. EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus, HER2 mut, ROS1 fus and MET mut were more likely to have RRM1 low expression and EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus and HER2 mut tend to have TS low expression. Wild‐type, EGFR L858R, EGFR rare mut and BRAF mut were associated with lower β‐tubulin III expression. In addition, wild‐type, RAS mut, ROS1 fus, BRAF and MET mut had higher proportions of PD‐L1 high expression, suggesting potential higher chance of response to PD‐(L)1 blocking therapies.

![Correlation between driver mutations and predictive markers](CAS-110-2014-g002){#cas14032-fig-0002}

###### 

The correlation between each driver mutation and the sensitivity markers

  Type                                 ERCC1 low %                                            RRM1 low %                                              TS low %                                                β‐tubulin III low %                                     PD‐L1 (+) %                                            Potential sensitive agents
  ------------------------------------ ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------
  Overall population (cut‐off value)   11.7 (68/583)                                          66.3 (386/582)                                          72.0 (420/583)                                          57.0 (345/605)                                          27.6 (145/525)                                         ‐
  Wild type                            14.9[a](#cas14032-note-0005){ref-type="fn"} (29/194)   50.0 (97/194)                                           54.6 (106/194)                                          61.8[a](#cas14032-note-0005){ref-type="fn"} (126/204)   36.4[a](#cas14032-note-0005){ref-type="fn"} (64/176)   Platinum/Taxanes/Vinorelbine/PD‐(L)1 inhibitors
  EGFR 19DEL                           2.9 (4/138)                                            76.8[a](#cas14032-note-0005){ref-type="fn"} (106/138)   87.6[a](#cas14032-note-0005){ref-type="fn"} (120/137)   58.9 (83/141)                                           16.1 (20/124)                                          Gemcitabine/Pemetrexed
  EGFR L858R                           7.2 (10/139)                                           81.2[a](#cas14032-note-0005){ref-type="fn"} (112/138)   82.7[a](#cas14032-note-0005){ref-type="fn"} (115/139)   60.3[a](#cas14032-note-0005){ref-type="fn"} (85/142)    18.9 (23/122)                                          Gemcitabine/Pemetrexed/Taxanes
  EGFR rare                            16.7[a](#cas14032-note-0005){ref-type="fn"} (2/12)     91.7[a](#cas14032-note-0005){ref-type="fn"} (11/12)     100[a](#cas14032-note-0005){ref-type="fn"} (12/12)      85.7[a](#cas14032-note-0005){ref-type="fn"} (12/14)     20.0 (3/15)                                            Platinum/Gemcitabine/Pemetrexed/Vinorelbine/
  ALK                                  22.7[a](#cas14032-note-0005){ref-type="fn"} (5/22)     69.6[a](#cas14032-note-0005){ref-type="fn"} (16/23)     95.7[a](#cas14032-note-0005){ref-type="fn"} (22/23)     39.1 (9/23)                                             25.0 (5/20)                                            Platinum/Gemcitabine/Pemetrexed
  HER2                                 .0(0/1)                                                **100** [a](#cas14032-note-0005){ref-type="fn"} (1/1)   100[a](#cas14032-note-0005){ref-type="fn"} (1/1)        .0 (0/1)                                                ‐                                                      Gemcitabine/Pemetrexed
  RAS                                  28.6[a](#cas14032-note-0005){ref-type="fn"}(16/56)     58.9 (33/56)                                            58.9 (33/56)                                            39.0 (23/59)                                            44.9[a](#cas14032-note-0005){ref-type="fn"} (22/49)    Platinum/PD‐(L)1 inhibitors
  RET                                  14.3[a](#cas14032-note-0005){ref-type="fn"}(1/7)       50.0 (3/6)                                              57.1 (4/7)                                              28.6 (2/7)                                              .0 (0/6)                                               Platinum
  ROS1                                 .0(0/6)                                                66.7[a](#cas14032-note-0005){ref-type="fn"} (4/6)       66.7 (4/6)                                              14.3 (1/7)                                              60.0[a](#cas14032-note-0005){ref-type="fn"} (3/5)      Gemcitabine/PD‐(L)1 inhibitors
  BRAF                                 .0(0/5)                                                20.0 (1/5)                                              40.0 (2/5)                                              60[a](#cas14032-note-0005){ref-type="fn"} (3/5)         60.0[a](#cas14032-note-0005){ref-type="fn"} (3/5)      Taxanes/Vinorelbine/PD‐(L)1 inhibitors
  MET (mut)                            33.3[a](#cas14032-note-0005){ref-type="fn"}(1/3)       66.7[a](#cas14032-note-0005){ref-type="fn"} (2/3)       33.3 (1/3)                                              33.3 (1/3)                                              66.7[a](#cas14032-note-0005){ref-type="fn"} (2/3)      Platinum/Gemcitabine/PD‐(L)1 inhibitors

Low expression of ERCC1, RRM1, TS and β‐tubulin III indicate better sensitivity to platinum, gemcitabine, pemetrexed and anti--microtubule agents, respectively, while positive/higher PD‐L1 expression indicates better sensitivity to PD‐(L)1 inhibitors. The percentage of favorable expression of each marker (low ERCC1, low RRM1, low TS, low β‐tubulin III and positive PD‐L1) in overall population is used as the cut‐off value.

ERCC1, excision repair cross‐complementation group 1; fus, fusion; mut, mutation; PD‐(L)1, programmed death‐ligand 1; RRM1, ribonucleotide reductase subunit M1; TS, thymidylate synthase.

The rate was higher than the general level, and the drugs in the last column were considered sensitive to patients with certain genotype.

Green shades mean that the rate was higher than the general level.

John Wiley & Sons, Ltd

3.4. Pilot validation of sensitivity prediction {#cas14032-sec-0014}
-----------------------------------------------

Anti--microtubule drugs, rather than anti--metabolic agents, were consistent with recommendation in wild‐type patients. Group A has 10 advanced NSCLC patients, while group B has 11 patients. There was no significant difference in gender (male 10/8, *P* = 0.074) between them, while group A was older than group B (63.3 ± 6.1/52.6 ± 8.4, *P* = 0.004). Patients in group A had higher DoR and ORR (31.2%/60.0%) than group B (26.6%/45.5%), consistent with our recommendation of anti--microtubules, such as taxanes and vinorelbine, in the treatment of NSCLC patients without active driver mutations.

4. DISCUSSION {#cas14032-sec-0015}
=============

All previous treatment strategies for NSCLC patients were based on the whole population. It is now known that genotyping determines not only the targeted therapy options but also the biological behavior of the tumor, thus different treatment strategies. Therefore, it is necessary to re‐examine the conclusions of treatment strategies based on the general population in the past. One of the treatment strategies is traditional chemotherapy regimen selection. Targeted therapy has been the first choice for NSCLC patients with typical gene mutation, such as EGFR and ALK. However, the treatment of cancer is a long‐term process and the acquired resistance of targeted drugs is inevitable. Furthermore, for patients harboring known gene mutations with no available targeted therapy options, chemotherapy or immunotherapy is still the standard of care.

The present study assessed the relationship between genotyping for 8 important driver genes and some outcomes of sensitivity markers of chemotherapy and immunotherapy in a large sample of NSCLC patients. EGFR mutations were still the most common gene alterations in NSCLC patients, followed by RAS and ALK. The genotyping results agreed with previous studies in the prevalence of driver mutations in Chinese NSCLC patients.[12](#cas14032-bib-0012){ref-type="ref"} The low expression rate of ERCC1, RRM1, TS and β‐tubulin III, and the PD‐L1 positive rate, differing from other studies, might be due to, for instance, different races, proportions of histology and stages.[13](#cas14032-bib-0013){ref-type="ref"}, [14](#cas14032-bib-0014){ref-type="ref"}, [15](#cas14032-bib-0015){ref-type="ref"} In particular, the issue of ERCC1 isoform and PD‐L1 antibody selection for IHC is worth mentioning. Friboulet et al[16](#cas14032-bib-0016){ref-type="ref"} detected and elaborated on the function of ERCC1 isoform 202 for nucleotide excision repair and cisplatin resistance. While ERCC1 monoclonal 4F9 is the specific antibody of ERCC1 isoform 202, all specimen samples in our study were tested by ERCC1 monoclonal 4F9 (clone UMAB8, Beijing Zhongshan Golden Bridge Biotechnology). Therefore, the lower expression of ERCC1 in our study means a lower expression of ERCC1 isoform 202 and the patients with lower ERCC1 isoform 202 expression are more sensitive to platinum. In addition, the study BLUEPRINT showed that the expression of PD‐L1 detected by SP142 antibody is lower than other PD‐L1 antibodies, but SP142 antibody, 22C3 antibody and other PD‐L1 antibodies have highly consistency.[17](#cas14032-bib-0017){ref-type="ref"} In addition, every PD‐L1 inhibitor needs to match certain PD‐L1 detecting antibody(s), and there is still no consensus on which is the optimal PD‐L1 detecting antibody. In the initial stage of our PD‐L1 study, the pathology department of our hospital used antibody SP142 for all NSCLC patients. The aim of the present study was to detect the expression of PD‐L1 for the whole population to obtain a general level rather than for the expression of one certain patient to select drugs. Therefore, we consider SP142 to be reasonable on that basis.

Some previous studies have demonstrated the relationship between predictive markers and certain chemo agents or targeted drugs. The results revealed that tumor histology also had an impact on their correlation. Low expression of ERCC1 can predict higher objective response of platinum‐based therapy in NSCLC patients with better outcome,[18](#cas14032-bib-0018){ref-type="ref"}, [19](#cas14032-bib-0019){ref-type="ref"} and squamous patients seemed to benefit more.[20](#cas14032-bib-0020){ref-type="ref"} Patients with high RRM1 expression showed resistance to gemcitabine.[9](#cas14032-bib-0009){ref-type="ref"} A low level of TS expression was related to clinical benefit from pemetrexed therapy.[21](#cas14032-bib-0021){ref-type="ref"} Combining data from 10 studies supported that β‐tubulin III could be a predictive factor for sensitivity to chemotherapy regimens containing taxanes or vinorelbine, the ORR of the chemotherapy was significantly higher in patients with low/negative expression.[22](#cas14032-bib-0022){ref-type="ref"} PD‐L1 expression enhanced the efficacy of nivolumab.[10](#cas14032-bib-0010){ref-type="ref"}

Based on the above results, as well as different driver gene mutations, we recommended some alternative drugs for NSCLC patients who became resistant to targeted therapy or had no optimal targeted drugs. Although there is a limitation that the data for IHC staining in the validation cohort is not applicable, the small sample test results validated our recommendation: that is to say, NSCLC patients with no EGFR mutations will have better outcomes by using anti--microtubule drugs rather than gemcitabine or pemetrexed. Few studies focus on the treatment of NSCLC patients with EGFR wild‐type. A Japanese study revealed that pemetrexed‐carboplatin combination was effective and well‐tolerated in EGFR wild‐type non--squamous NSCLC patients, resulting in an ORR of 35.8%,[22](#cas14032-bib-0022){ref-type="ref"} which was lower than the ORR of group A (45.5%) in our study. The difference may be caused by small sample and NSCLC histology. Therefore, a large randomized clinical trial on the treatment efficacy comparison between anti--microtubules and gemcitabine or pemetrexed is needed.

Referring to the results, some drug sensitivity indications were consistent with previous reports in some respects. For example, NSCLC patients with ALK+ responded well to pemetrexed‐based therapy, obtaining prolonged progression‐free survival.[23](#cas14032-bib-0023){ref-type="ref"} For advanced NSCLC patients with KRAS mutations, who were considered chemo‐resistant,[24](#cas14032-bib-0024){ref-type="ref"} PD‐(L)1 inhibitors were available[25](#cas14032-bib-0025){ref-type="ref"} and platinum‐based chemotherapy were added.[26](#cas14032-bib-0026){ref-type="ref"} BRAF mutation in Chinese NSCLC patients was rare, with patients not responding well to chemotherapy,[27](#cas14032-bib-0027){ref-type="ref"} and limited data available. Anti PD‐(L)1 was optional and taxanes might be the most sensitive chemo agents. For EGFR‐mutant patients, PD‐(L)1 inhibitors were not recommended,[26](#cas14032-bib-0026){ref-type="ref"} while patient with KARS, BRAF and MET mutations benefit more from immune checkpoint inhibitors than EGFR, ALK and RET patients.[25](#cas14032-bib-0025){ref-type="ref"}, [28](#cas14032-bib-0028){ref-type="ref"} With the common practice of gene mutation detection, there will be more evidence from qualified clinical studies to support these results.

Our study has provided enlightenment for clinical practice. On the one hand, detection of gene mutations can help in selecting the best available drugs for targeted therapy. On the other hand, for the patients with drug resistance after targeted cancer therapies and without specific targeted therapies, the analysis of the predictive markers of chemotherapy and immunotherapy efficacy can provide an important reference to choose the optimal chemotherapy and assess whether it is suitable for immunotherapy. In addition, the results explain why patients differ in sensitivity to various drugs from the perspective of gene mutations.

It is noteworthy that there is no clear conclusion on the relationship between predictive markers and chemotherapy efficacy; large randomized studies are needed to determine their predictive value in different settings and tumors. And for our study, there is still a need for follow‐up studies to analyze the data of patients receiving these drugs and to verify the clinical significance of this study. In the future, precise treatment will be the key point in drug research and development, and more specific and selective biomarkers will be identified. Furthermore, a feasible method of continuous dynamic detection of biomarkers, especially liquid biopsy, will play an important role both in drug guidance and resistance. Thus, patients receiving individualized treatment will benefit more.
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